ALLMedicine™ Multiple Sclerosis Center

Jun 28th, 2022 - Neuronal damage is the primary cause of long-term disability of multiple sclerosis (MS) patients. Assessment of axonal integrity from diffusion MRI parameters might enable better disease characterisation. 16 diffusion derived measurements from dif...

Jun 28th, 2022 - Lysophospholipids (LPLs) are bioactive lipids that include sphingosine 1-phosphate (S1P), lysophosphatidic acid, etc. S1P, a metabolic product of sphingolipids in the cell membrane, is one of the best-characterized LPLs that regulates a variety of...

Jun 28th, 2022 - The possibility to better predict the severity of the disease in a patient newly diagnosed with multiple sclerosis would allow the treatment strategy to be personalized and lead to better clinical outcomes. Prognostic biomarkers are highly needed....

Jun 27th, 2022 - Most disease-modifying therapies (DMTs) approved for the treatment of multiple sclerosis (MS) are not recommended during pregnancy, and discouraged while breastfeeding. However, discontinuation of some DMTs before pregnancy can leave women vulnera...

Jun 27th, 2022 - Fatigue is one of the leading causes of reduced quality of life and inability to work in people with multiple sclerosis (pwMS). Currently, no treatment effectively ameliorates fatigue. We still know little about what causes fatigue and which facto...

Jun 18th, 2022 - Supporting the Role of Parenting for People with Multiple Sclerosis: A Guide for Clinicians.|2022|Rider JV,Selim J,|

Sep 29th, 2020 - Vision Problems in Multiple Sclerosis.|2020|Costa SL,Pandey K,Hrdina J,Rondon M,Devos H,|

Jul 18th, 2020 - There is an unmet need in multiple sclerosis (MS) therapy for treatments to stop progressive disability. The development of treatments may be accelerated if novel biomarkers are developed to overcome the limitations of traditional imaging outcomes...

May 14th, 2020 - Practical Sleep Information for People With Multiple Sclerosis.|2020|Siengsukon C,Karahan AY,Strober L,|

Jun 5th, 2019 - To establish recommendations on immunization for patients with multiple sclerosis (MS) BACKGROUND: Vaccines have been suspected in the past to trigger MS and relapses. With the extension of the immunoactive treatment arsenal, other concerns have b...

Jun 24th, 2022 - Objective: The goal of this protocol is to understand how the pathology of multiple sclerosis (MS) relates to its evolution over time as observed through neuroradiological, clinical, and biological data collection in vivo. Study population: This s...

Jun 24th, 2022 - The objective of this study is to examine the risk factors and natural course of JCV infection and progressive multifocal leukoencephalopathy (PML). PML is a devastating, demyelinating neurological disease affecting the brain of patients with a co...

Jun 24th, 2022 - Objectives. The primary aim of this pilot study is to assess the effects of short-term, high-dose corticosteroid administration on the 12-week evolution of multiple sclerosis lesions with centripetal enhancement pattern on magnetic resonance imagi...

Jun 24th, 2022 - Objective. The overall objective of this study is to investigate the genetic, immune, and neuroimaging profiles that may increase a person s risk of developing multiple sclerosis (MS) in order to identify and validate predictive biomarkers in popu...

Jun 24th, 2022 - Objective The goals of this pilot study are: To assess the degree to which subacute changes in clinical, electrophysiological, and imaging measures can robustly predict retinal neuronal loss 12 months after acute optic neuritis. To construct a com...

Jun 23rd, 2022 - DENVER – Monoclonal antibodies, antivirals, immunomodulators, and pulmonary arterial vasodilators top the list of drugs that were most frequently implicated as causes of headaches in a federal side effect database that anyone can contribute to, ac.

Jun 23rd, 2022 - DENVER, Colorado — Monoclonal antibodies, antivirals, immunomodulators, and pulmonary arterial vasodilators top the list of drugs that were most frequently implicated as causes of headaches in a federal side effect database that anyone can contrib...

Jun 22nd, 2022 - The novel drug vidofludimus calcium (Immunic Therapeutics) is safe and effective for patients with relapsing-remitting multiple sclerosis (RRMS), new research suggests. Vidofludimus calcium is an investigational oral second-generation selective di...

Jun 21st, 2022 - NATIONAL HARBOR, Maryland ― The latest updates on COVID-19 vaccination response among patients with multiple sclerosis (MS) who are treated with disease-modifying therapy (DMT) show that if patients do contract the virus, cases are mild, and serio...

Jun 20th, 2022 - NATIONAL HARBOR, Maryland — The first randomized trial to examine whether older adults with multiple sclerosis (MS) can safely discontinue disease-modifying therapy (DMT) after years of being relapse-free failed to deliver a definitive conclusion....